Qutenza Approval History
FDA Approved: Yes (First approved November 16, 2009)
Brand name: Qutenza
Generic name: capsaicin
Dosage form: Transdermal Patch
Previous Name: NGX-4010
Company: NeurogesX, Inc.
Treatment for: Postherpetic Neuralgia
Qutenza, formerly NGX-4010, is a capsaicin transdermal patch for the management of pain due to postherpetic neuralgia.
Development History and FDA Approval Process for Qutenza
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.